Skip to main content
. Author manuscript; available in PMC: 2022 Jun 15.
Published in final edited form as: Clin Cancer Res. 2021 Oct 1;27(24):6677–6686. doi: 10.1158/1078-0432.CCR-21-2199

FIG 5.

FIG 5.

Efficacy in all patients with BRCA alterations (BRCA+) detected by central plasma or tissue testing, regardless of enrollment assay. Patient groups overlap but are not identical: 61 patients were identified as BRCA+ by central plasma test (A) and 59 patients were identified as BRCA+ by central tissue test (B). Bars were capped at 100% for visual clarity. PSA increases for the 3 leftmost patients in panel A were 689%, 231%, and 183%.